Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExoFlo for Post-Acute and Chronic Post-COVID-19 Syndrome
NCT05116761Phase 2Withdrawn
- Sponsor
- Direct Biologics
- Start
- Nov 2024
- Primary completion
- Nov 2024
- Modality
- Lipid-based Nanoparticles, Cell Therapies
01
Overview
Phase 2, randomised, double-blind trial in post acute COVID-19 syndrome comparing Placebo with ExoFlo (2 arms). Primary endpoints: Six Minute Walk Test distance at 61 Days and Incidence of Serious Adverse Events at 61 Days. Planned start Nov 2024; status: withdrawn.
02
Drugs
bone marrow mesenchymal stem cell derived extracellular vesicles
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT05116761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116761.